Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
暂无分享,去创建一个
Rachel Schiff | R. Schiff | C. Osborne | G. Arpino | C Kent Osborne | Grazia Arpino | L. Wiechmann | Lisa Wiechmann
[1] A. Giobbie-Hurder,et al. Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. , 2009 .
[2] E. Levin. Plasma membrane estrogen receptors , 2009, Trends in Endocrinology & Metabolism.
[3] C. Lange. Integration of progesterone receptor action with rapid signaling events in breast cancer models , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[4] E. Levin,et al. Estrogen receptors outside the nucleus in breast cancer , 2008, Breast Cancer Research and Treatment.
[5] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Dowsett,et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo , 2007, Molecular Cancer Therapeutics.
[7] W. Zwart,et al. PKA‐induced resistance to tamoxifen is associated with an altered orientation of ERα towards co‐activator SRC‐1 , 2007, The EMBO journal.
[8] R. Sainson,et al. A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.
[9] A. Brodie,et al. Xenograft models for aromatase inhibitor studies , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[10] D. Rimm,et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Schiff,et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. , 2007, Journal of the National Cancer Institute.
[12] Eric J Feuer,et al. The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.
[13] John M.S. Bartlett,et al. Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients , 2007, Clinical Cancer Research.
[14] J. Ostrander,et al. Linkage of progestin and epidermal growth factor signaling: Phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth , 2007, Steroids.
[15] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[16] J. Forbes,et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] D. Márquez,et al. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor , 2001, Endocrine.
[18] M. Ellis,et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers , 2007, Breast Cancer Research and Treatment.
[19] V. Jordan,et al. Steroid receptors and their role in the biology and control of breast cancer growth. , 2006, Seminars in oncology.
[20] Y. Li,et al. Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist , 2006, Science.
[21] M. Ellis,et al. Can Molecular Markers Predict When to Implement Treatment With Aromatase Inhibitors in Invasive Breast Cancer , 2006 .
[22] E. Levin,et al. Nature of functional estrogen receptors at the plasma membrane. , 2006, Molecular endocrinology.
[23] S. Hilsenbeck,et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. , 2006, Cancer research.
[24] M. Ellis,et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Deuel,et al. A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling , 2006 .
[26] P. Hegde,et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[27] W. Welshons,et al. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer , 2006, Molecular and Cellular Endocrinology.
[28] C. J. Barnes,et al. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. , 2006, Cancer research.
[29] F. Khuri,et al. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. , 2006, Oncology.
[30] R. Nicholson,et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. , 2005, Endocrinology.
[31] Adrian V. Lee,et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Cuzick,et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Adrian V. Lee,et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. , 2005, Journal of the National Cancer Institute.
[34] Robert B Livingston,et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.
[35] J. Baselga,et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Suzanne F. Jones,et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W. Carney,et al. Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy , 2005, Cancer.
[39] R. Schiff,et al. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. , 2005, Endocrine-related cancer.
[40] Simak Ali,et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. , 2005, The Lancet. Oncology.
[41] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[42] R. Schiff,et al. Aromatase inhibitors: Future directions , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[43] R. Schiff,et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Ellis,et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Dowsett,et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Ellis,et al. Synergistic Interactions Between Tamoxifen and Trastuzumab (Herceptin) , 2005 .
[47] Rachel Schiff,et al. Estrogen-receptor biology: continuing progress and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] C. Mineo,et al. Dissecting the basis of nongenomic activation of endothelial nitric oxide synthase by estradiol: role of ERalpha domains with known nuclear functions. , 2005, Molecular endocrinology.
[49] S. Johnston. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. , 2005, Clinical Cancer Research.
[50] K. Blackwell,et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. , 2005, Cancer research.
[51] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[52] F. Ciardiello,et al. AMeta-Analysis on the Interaction between HER-2 Expression and Response to EndocrineTreatment in Advanced Breast Cancer , 2005 .
[53] C. Lange,et al. Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2 , 2004, Molecular and Cellular Biology.
[54] Qing Lu,et al. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[55] R. Nicholson,et al. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. , 2004, Endocrine-related cancer.
[56] Manuel Hidalgo,et al. Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.
[57] Heidi L. Weiss,et al. Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.
[58] J. Qin,et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. , 2004, Molecular cell.
[59] A. Howell,et al. Steroid receptors in human breast cancer , 2004, Trends in Endocrinology & Metabolism.
[60] R. Nicholson,et al. Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells , 2004, Breast Cancer Research and Treatment.
[61] C. Osborne,et al. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[62] X. Guan,et al. Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer , 2004, Clinical Cancer Research.
[63] W. Gradishar. Tamoxifen--what next? , 2004, The oncologist.
[64] E. Rosen,et al. BRCA1 Inhibits Membrane Estrogen and Growth Factor Receptor Signaling to Cell Proliferation in Breast Cancer , 2004, Molecular and Cellular Biology.
[65] Tanja Fehm,et al. HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[67] C. J. Barnes,et al. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells , 2004, FEBS letters.
[68] M. Ellis. Overcoming endocrine therapy resistance by signal transduction inhibition. , 2004, The Oncologist.
[69] P. Lønning. Aromatase inhibitors in breast cancer. , 2004, Endocrine-related cancer.
[70] B. Komm,et al. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. , 2004, Molecular endocrinology.
[71] Christopher J. Barnes,et al. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[72] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[73] R. Nicholson,et al. Nonendocrine Pathways and Endocrine Resistance , 2004, Clinical Cancer Research.
[74] Andrew Kramar,et al. Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy , 2002, Breast Cancer Research and Treatment.
[75] Ji-ping Wang,et al. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells , 2000, Breast Cancer Research and Treatment.
[76] S. Franco,et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] M. Dowsett. Biomarker investigations from the ATAC trial: the role of TA01 , 2004, Breast Cancer Research and Treatment.
[78] M. Gottardis,et al. Regulation of estrogen receptor expression , 2004, Breast Cancer Research and Treatment.
[79] E. Perez,et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .
[80] R. Nicholson,et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. , 2003, Endocrinology.
[81] Barry Komm,et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.
[82] Boris Freidlin,et al. Targeting epidermal growth factor receptor—are we missing the mark? , 2003, The Lancet.
[83] M. Martin,et al. Estrogen-like activity of metals in MCF-7 breast cancer cells. , 2003, Endocrinology.
[84] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] A. Wellstein,et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. , 2003, Molecular endocrinology.
[86] Lei Li,et al. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[87] Ping Zhang,et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. , 2003, Molecular endocrinology.
[88] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[89] G. Alton,et al. Identification of a Structural Determinant , 2002 .
[90] E. Levin. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.
[91] R. Nicholson,et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.
[92] P. Blackmore,et al. Membrane receptors for steroid hormones: Signal transduction and physiological significance , 2003, Journal of cellular biochemistry.
[93] D. DeMets,et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] E. Levin,et al. Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.
[95] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[96] G. Figtree,et al. Truncated Estrogen Receptor &agr; 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase , 2003, Circulation.
[97] R. Schiff,et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[98] M. Dowsett,et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] C. Hughes,et al. Integration of the Non-genomic and Genomic Actions of Estrogen , 2002, The Journal of Biological Chemistry.
[100] A. Lipton,et al. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. , 2002, Oncology reports.
[101] Chi-Wai Wong,et al. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[102] Hong Ma,et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.
[103] V. Speirs,et al. Oestrogen receptor beta: how should we measure this? , 2002, British Journal of Cancer.
[104] C. J. Barnes,et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.
[105] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[106] J. Qin,et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.
[107] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] John H. White,et al. Diversity in the mechanisms of gene regulation by estrogen receptors. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[109] Simak Ali,et al. Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.
[110] Chi-Hung Lin,et al. Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer , 2002, International journal of cancer.
[111] E. Levin,et al. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. , 2002, Molecular endocrinology.
[112] R. Schiff,et al. Estrogen receptor: current understanding of its activation and modulation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[113] Adrian V. Lee,et al. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[114] K. Lackey,et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.
[115] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] K. Horwitz,et al. Transcriptional Hyperactivity of Human Progesterone Receptors Is Coupled to Their Ligand-Dependent Down-Regulation by Mitogen-Activated Protein Kinase-Dependent Phosphorylation of Serine 294 , 2001, Molecular and Cellular Biology.
[117] D. Márquez,et al. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells , 2001, Oncogene.
[118] M. Dowsett,et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[119] M. Wyckoff,et al. Plasma Membrane Estrogen Receptors Are Coupled to Endothelial Nitric-oxide Synthase through Gαi * , 2001, The Journal of Biological Chemistry.
[120] C. Klinge. Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.
[121] R. Nicholson,et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.
[122] C. Turck,et al. Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity* , 2001, The Journal of Biological Chemistry.
[123] K. Mokbel,et al. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[124] Simak Ali,et al. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.
[125] C. Klinge,et al. Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor α 1 Supported by NIH R01 DK 53220 and a University of Louisville School of Medicine Research Grant to C.M.K. 1 , 2001, Molecular and Cellular Endocrinology.
[126] S. Safe. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. , 2001, Vitamins and hormones.
[127] L. Harris,et al. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. , 2001, European journal of cancer.
[128] T. Löning,et al. Progesterone Receptor Isoforms, PR-B and PR-A, in Breast Cancer: Correlations with Clinicopathologic Tumor Parameters and Expression of AP-1 Factors , 2001, Hormone Research in Paediatrics.
[129] B. Katzenellenbogen,et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. , 2000, Recent progress in hormone research.
[130] B. Katzenellenbogen,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I* , 2000 .
[131] D. Agard,et al. Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[132] D. Berry,et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] A. Lenferink,et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.
[134] K. Horwitz,et al. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer , 2000, Steroids.
[135] Sun,et al. Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells , 2000, European journal of cancer.
[136] E. Levin,et al. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. , 2000, Molecular endocrinology.
[137] M. Privalsky,et al. The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.
[138] J. Font de Mora,et al. AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.
[139] S. Martino,et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.
[140] E. Levin,et al. Natriuretic Peptides Inhibit G Protein Activation , 2000, The Journal of Biological Chemistry.
[141] J. Chen,et al. The SRC family of nuclear receptor coactivators. , 2000, Gene.
[142] C. Lange,et al. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[143] D. McDonnell,et al. The Estrogen Receptor -isoform (er) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .
[144] C. Lange,et al. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. , 1999, Molecular endocrinology.
[145] R. Lanz,et al. Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.
[146] C. Clarke,et al. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women , 1999, British Journal of Cancer.
[147] G. Greene,et al. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. , 1999, Molecular endocrinology.
[148] J. Pasqualini. Progestins and breast cancer , 2007, The Journal of steroid biochemistry and molecular biology.
[149] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[150] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[151] K. Horwitz,et al. Convergence of Progesterone and Epidermal Growth Factor Signaling in Breast Cancer , 1998, The Journal of Biological Chemistry.
[152] N. Weigel,et al. Ligand-independent activation of steroid hormone receptors , 1998, Journal of Molecular Medicine.
[153] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[154] K.,et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[155] A. Ray,et al. Repression of interleukin‐6 gene expression by 17β‐estradiol: , 1997 .
[156] B. O’Malley,et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.
[157] D. Picard,et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.
[158] Daniel Metzger,et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.
[159] I. Ellis,et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.
[160] Thorsten Heinzel,et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.
[161] R. Evans,et al. A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.
[162] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[163] M. Sliwkowski,et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.
[164] I. Ellis,et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. , 1993, European journal of cancer.
[165] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[166] N. Normanno,et al. Regulation by Estrogen through the 5′-Flanking Region of the Transforming Growth Factor α Gene , 1991 .
[167] H. Gronemeyer,et al. Transcription activation by estrogen and progesterone receptors. , 1991, Annual review of genetics.
[168] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[169] M. Dowsett,et al. Aromatase inhibitors in human breast cancer , 1989 .
[170] W. McGuire,et al. The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.